trial

Energy Homeostasis Under Treatment With Atypical Antipsychotics

NCTId NCT00148564
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase 4 · Completed
Enrollment 40 (actual)
Sponsored by Charite University, Berlin, Germany
Primary completion 2007-03
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Phase 4
Status
Completed
Enrollment
40 (actual)
Study type
Interventional
Allocation
Randomized
Model
Parallel
Masking
None
Start
2004-03
Primary completion
2007-03
Eligibility
ALL · 18 Years · 60 Years

Interventions & indications

Drugs
OlanzapineZiprasidone

Sponsors

Charite University, Berlin, GermanyLead Sponsor

Investigators

1
Martin Schaefer, MDPrincipal Investigator

Sites

1 total
Berlin, Germany

Facts & assertions

4 sourced
Enrollment
40
Phase
PHASE4
Primary Completion Date
2007-03
Status
COMPLETED
relationships
The graph out of here
drug
Olanzapine
drug
Ziprasidone
drug
lead_sponsor
Charite University, Berlin, Germany
company
indication
Schizophrenia
indication
Schizophrenia
indication
Weight Gain
indication
investigator
Martin Schaefer, MD
person